Loading...

PerCP/Cyanine5.5 anti-mouse CD45 Antibody

Pricing & Availability
Clone
30-F11 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5, LCA
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
30-F11_PerCPCyanine55_CD45_Antibody_082418
C57BL/6 mouse splenocytes were stained with CD45 (Clone 30-F11) PerCP/Cyanine5.5 (filled histogram), or rat IgG2b, κ PerCP/Cyanine5.5 isotype control (open histogram).
  • 30-F11_PerCPCyanine55_CD45_Antibody_082418
    C57BL/6 mouse splenocytes were stained with CD45 (Clone 30-F11) PerCP/Cyanine5.5 (filled histogram), or rat IgG2b, κ PerCP/Cyanine5.5 isotype control (open histogram).
Compare all formats See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
103131 25 µg 70€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103132 100 µg 177€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Additional Product Notes
BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Shah D, et al. 2021. Oncoimmunology. 10:1939601. PubMed
  2. Xiang G, et al. 2022. Cell Death Dis. 13:451. PubMed
  3. Pani F, et al. 2021. Endocrinology. 162:. PubMed
  4. Xuan W, et al. 2022. Cancer Immunol Res. 10:770. PubMed
  5. Liu W, et al. 2022. Biomedicines. 10: . PubMed
  6. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  7. Wu X, et al. 2022. J Clin Med. 11: . PubMed
  8. Xie DH, et al. 2022. Med Phys. 49:6728. PubMed
  9. Poh AR, et al. 2022. Cell Rep. 41:111479. PubMed
  10. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  11. Mansouri S, et al. 2022. J Immunol. 209:2114. PubMed
  12. Lai C, et al. 2023. J Bone Miner Res. 38:86. PubMed
  13. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  14. Xu H, et al. 2022. Aging Dis. 13:1875. PubMed
  15. Zha AH, et al. 2022. Lupus Sci Med. 9: . PubMed
  16. Guo J, et al. 2023. Cell Rep Med. 4:100881. PubMed
  17. Yang L, et al. 2023. Acta Pharmacol Sin. :. PubMed
  18. Liu G, et al. 2023. Commun Biol. 6:102. PubMed
  19. Chan L, et al. 2023. Int J Mol Sci. 24: . PubMed
  20. Kuehm LM, et al. 2021. Cancer Immunol Res. 9:227. PubMed
  21. Khan NZ, et al. 2021. Brain Behav Immun. 92:165. PubMed
  22. Na E, et al. 2022. Am J Physiol Lung Cell Mol Physiol. 322:L550. PubMed
  23. Tang Y, et al. 2022. Dev Cell. 57:480. PubMed
  24. Li X, et al. 2022. Cell. 185:1709. PubMed
  25. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
  26. Tan L, et al. 2022. Aging Dis. 13:1562. PubMed
  27. Jung IY, et al. 2022. Sci Transl Med. 14:eabn7336. PubMed
  28. Zhang Q, et al. 2022. Nat Metab. 4:1055. PubMed
  29. Bermea KC, et al. 2022. J Vis Exp. . PubMed
  30. Bajaj R, et al. 2022. Cell Rep. 40:111429. PubMed
  31. Zimmerman SM, et al. 2022. Oncogene. 41:4983. PubMed
  32. Axelrod ML, et al. 2022. Nature. 611:818. PubMed
  33. Pagni RL, et al. 2022. Front Immunol. 13:1005937. PubMed
  34. Fei F, et al. 2022. Int J Mol Sci. 23:. PubMed
  35. Shi H, et al. 2022. Nutrients. 14:. PubMed
  36. Li J, et al. 2022. Elife. 11:. PubMed
  37. Matsuzawa M, et al. 2023. Nat Commun. 14:1417. PubMed
  38. Xiao Y, et al. 2023. EMBO J. 42:e111762. PubMed
  39. He Y, et al. 2023. Biomolecules. 13:. PubMed
  40. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  41. Doloff JC, et al. 2023. Sci Adv. 9:eade9488. PubMed
  42. Choi JG, et al. 2020. Front Immunol. 11:598556. PubMed
  43. Gogoi H, et al. 2020. Front Immunol. 1.620833333. PubMed
  44. Daemen S, et al. 2021. Cell Reports. 34(2):108626. PubMed
  45. Zaman R, et al. 2021. Immunity. :. PubMed
  46. Ramakrishna C, et al. 2019. Nat Commun. 10:2153. PubMed
  47. Tan L, et al. 2022. Biochem Biophys Rep. 32:101351. PubMed
  48. Padonou F, et al. 2022. EMBO Rep. 23:e53576. PubMed
  49. Golden GJ, et al. 2021. MBio. 12:e0118121. PubMed
  50. Taddeo A, et al. 2022. NPJ Vaccines. 7:82. PubMed
  51. Li Y, et al. 2022. Int J Biol Sci. 18:3697. PubMed
  52. Tatsuguchi T, et al. 2022. Int Immunol. 34:277. PubMed
  53. Li Z, et al. 2021. Immunology. 163:105. PubMed
  54. Krausgruber T, et al. 2020. Nature. 583:296. PubMed
  55. Kawano H, et al. 2016. Int Immunol. 28: 489 - 501. PubMed
  56. Liu W, et al. 2020. Mol Ther Oncolytics. 17:350. PubMed
  57. Yang H, et al. 2019. Mol Metab. 23:24. PubMed
  58. Alissafi T, et al. 2018. J Clin Invest. 128:3840. PubMed
  59. Hanhai Z, et al. 2021. Aging (Albany NY). 13:13108. PubMed
  60. Song J, et al. 2021. J Am Heart Assoc. 10:e017329. PubMed
  61. Sasse C, et al. 2022. Pathogens. 11:. PubMed
  62. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  63. Browning D, et al. 2017. Gene Ther. 10.1038/gt.2016.88. PubMed
  64. Rodda LB et al. 2018. Immunity. 48(5):1014-1028 . PubMed
  65. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  66. Hsu SPC, et al. 2020. J Neurooncol. 146:417. PubMed
  67. Yang M, et al. 2020. Cell Prolif. 53:e12784. PubMed
  68. Jazowiecka-Rakus J, et al. 2021. Cancers (Basel). 13:. PubMed
  69. Ren J, et al. 2021. Theranostics. 11:304. PubMed
  70. Craver BM, et al. 2020. Blood Adv. 4:312. PubMed
  71. Chen M, et al. 2021. Cancers (Basel). 13:. PubMed
  72. Garcia–Agudo LF, et al. 2019. FASEB J. :fj201900337R. PubMed
  73. Zaytseva D, et al. 2018. Physiol Rep. 6:e13812. PubMed
  74. Schmidleithner L et al. 2019. Immunity. 50(5):1232-1248 . PubMed
  75. Biffi G, et al. 2018. Cancer Discov. 2:282. PubMed
  76. Helm M, et al. 2022. Life (Basel). 12:. PubMed
  77. Potluri HK, et al. 2022. J Immunother Cancer. 10:. PubMed
  78. Papafragkos I, et al. 2022. Front Immunol. 13:889075. PubMed
  79. Liang Z, et al. 2021. J Cell Physiol. 236:4725. PubMed
  80. Fernandez Garcia-Agudo L, et al. 2021. Cell Rep. 36:109548. PubMed
  81. Chung H, et al. 2021. Immune Netw. 21:e28. PubMed
  82. Shen H, et al. 2022. Nat Commun. 13:6030. PubMed
  83. Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed
  84. Jeong D, et al. 2021. eLife. 0.416666666666667. PubMed
  85. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  86. Damal Villivalam S, et al. 2020. Nat Commun. 4313:11. PubMed
  87. Chaurasiya S, et al. 2020. Oncoimmunology. 9:1729300. PubMed
  88. Somerville TD, et al. 2020. eLife. 9:e53381.. PubMed
  89. Zhong J, et al. 2018. Sci Adv. 4:eaas9864. PubMed
  90. Sakaguchi M, et al. 2022. Nat Commun. 13:6092. PubMed
  91. Chimenti I, et al. 2022. Cell Death Discov. 8:149. PubMed
  92. Liu Y, et al. 2022. Nat Commun. 13:2665. PubMed
  93. Wang C, et al. 2021. Cell Stem Cell. . PubMed
  94. Fachi JL, et al. 2020. J Exp Med. 217:00:00. PubMed
  95. Voisin M, et al. 2021. Commun Biol. 4:420. PubMed
  96. Edwards CJ, et al. 2021. Br J Cancer. . PubMed
  97. Peres-Emidio EC, et al. 2022. Front Cell Infect Microbiol. 12:811474. PubMed
  98. Cong M, et al. 2021. Methods Mol Biol. 2388:59. PubMed
  99. Vijay R, et al. 2015. J Exp Med. 212: 1851 - 1868. PubMed
  100. Fleury M, et al. 2015. Development. 142: 3307 - 3320. PubMed
  101. Osborne JK, et al. 2021. Cell Reports. 36(3):109408. PubMed
  102. Wei SC, et al. 2020. Cancer Discov. . PubMed
  103. Vasilijevic J, et al. 2017. PLoS Pathog. 13:e1006650. PubMed
  104. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  105. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  106. Alexander RK, et al. 2020. eLife. 9:e54090.. PubMed
  107. Wang W, et al. 2022. Aging Cell. 21:e13630. PubMed
  108. Lee J, et al. 2022. Nat Commun. 13:1516. PubMed
  109. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  110. Li Z, et al. 2022. J Exp Clin Cancer Res. 41:74. PubMed
  111. Frii J, et al. 2021. Immunity. 54(5):1002-1021.e10. PubMed
  112. Nicholas DA, et al. 2020. Scientific Reports. 10(1):13063. PubMed
  113. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  114. Linde N, et al. 2018. Nat Commun. 9:21. PubMed
  115. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  116. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  117. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
  118. Formaglio P, et al. 2021. Immunity. 54:2724. PubMed
  119. Grune J, et al. 2022. Nat Cardiovasc Res. 1:649. PubMed
  120. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
  121. Li N, et al. 2021. eLife. 10:00. PubMed
  122. Zhao J, et al. 2018. Stem Cell Reports. 10:180. PubMed
  123. Yang J, et al. 2022. Microbiome. 10:149. PubMed
  124. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
  125. Yang Z, et al. 2021. Sci Adv. 7:. PubMed
  126. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  127. Myerson JW, et al. 2021. Nat Nanotechnol. Online ahead of print. PubMed
  128. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
  129. Hu Y, et al. 2021. Bioact Mater. 2905:6. PubMed
  130. Wen Y, et al. 2020. Hypertension. 869:75. PubMed
  131. Hsu CY, et al. 2020. Frontiers in Immunology. 11:574839. PubMed
  132. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  133. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  134. Adrover JM et al. 2019. Immunity. 50(2):390-402 . PubMed
  135. Christ A, et al. 2018. Cell. 172:162. PubMed
  136. Hepler C et al. 2018. eLife. 7 pii: e39636. PubMed
  137. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  138. Krueger A, et al. 2022. Front Microbiol. 12:789042. PubMed
  139. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  140. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  141. Liu Z, et al. 2015. Development. 142: 2452 - 2463. PubMed
  142. Wang Y, et al. 2020. Cell Death Dis. 1.169444444. PubMed
  143. Sharma M, et al. 2020. Circ Res. 127:335. PubMed
  144. Shao M, et al. 2021. Cell Stem Cell. 28(4):685-701.e7. PubMed
  145. Xiang W, et al. 2018. Nat Commun. 9:2574. PubMed
  146. Du Q et al. 2019. Dev Cell. 49(4):618-631 . PubMed
  147. Branchett WJ, et al. 2020. Wellcome Open Research. 0.278472222. PubMed
  148. Timblin GA, et al. 2021. Nat Metab. 3:618. PubMed
  149. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  150. Lang V, et al. 2021. Elife. 10:. PubMed
  151. Toth K, et al. 2022. PLoS Biol. 20:e3001526. PubMed
  152. Weinstock A, et al. 2021. Elife. :10. PubMed
  153. Joffin N, et al. 2021. Cell Stem Cell. 28(4):702-717.e8. PubMed
  154. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  155. Ballesteros I, et al. 2020. Cell. 183(5):1282-1297.e18. PubMed
  156. Alonso-Herranz L, et al. 2020. Elife. 9:00. PubMed
  157. Sun L, et al. 2015. Sci Rep. 5: 14871. PubMed
  158. Zhang Q, et al. 2021. Front Cell Dev Biol. 9:655552. PubMed
  159. Tuong ZK, et al. 2021. iScience. 24:103326. PubMed
  160. Thomas K, et al. 2022. JCI Insight. :. PubMed
  161. Xu X, et al. 2022. EMBO Rep. 23:e53509. PubMed
  162. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  163. Chandra J, et al. 2016. Immunol Cell Biol. 10.1038/icb.2016.83. PubMed
  164. Uematsu T, et al. 2016. Sci Rep. 6:37815. PubMed
  165. Alam Z, et al. 2020. Cell Rep. 107825:31. PubMed
  166. Gubin MM, et al. 2018. Cell. 175:1014. PubMed
  167. Li CJ, et al. 2018. J Clin Invest. 128:5251. PubMed
  168. Tao Z, et al. 2019. Clin Cancer Res. 25:1113. PubMed
  169. Xu G, et al. 2022. Front Pharmacol. 13:896601. PubMed
  170. Li M, et al. 2021. Cancers (Basel). 13:. PubMed
  171. Dong X, et al. 2022. Front Immunol. 13:896472. PubMed
  172. Pizzurro GA, et al. 2021. Cancers (Basel). 13:. PubMed
  173. Olson B, et al. 2021. Brain Behav Immun. 97:102. PubMed
  174. Calle P, et al. 2021. Cells. 10:. PubMed
  175. Shan B, et al. 2020. Nat Metab. 1332:2. PubMed
  176. Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed
  177. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  178. Kalafati L, et al. 2020. Cell. 183:771. PubMed
  179. Ngamsri KC, et al. 2020. Front Immunol. 11:407. PubMed
  180. Haider N, et al. 2020. Cell Commun Signal. 18:26. PubMed
  181. Bernstock JD, et al. 2019. J Allergy Clin Immunol. 145:358. PubMed
  182. Dahlgren MW et al. 2019. Immunity. 50(3):707-722 . PubMed
  183. Karolin A, et al. 2022. Front Pharmacol. 12:789080. PubMed
  184. Jazowiecka-Rakus J, et al. 2020. Mol Ther Oncolytics. 18:335. PubMed
  185. Wong NR, et al. 2021. Immunity. 54:2072. PubMed
  186. Upadhya R, et al. 2016. MBio. 7: 00547-16. PubMed
  187. Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed
  188. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  189. Ko HJ, et al. 2020. Front Immunol. 1897:11. PubMed
  190. Klose A, et al. 2018. JCSM Rapid Commun. 9:20222. PubMed
  191. Casanova-Acebes M, et al. 2018. J Exp Med. 215:2778. PubMed
  192. Chiang N, et al. 2019. J Clin Invest. 129:5294. PubMed
  193. Scott NA, et al. 2018. Front Immunol. 2.319444444. PubMed
  194. Mello AM, et al. 2022. Oncogenesis. 11:56. PubMed
  195. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  196. Sánchez-del-Campo L, et al. 2021. J Exp Clin Cancer Res. 40:117. PubMed
  197. Steele NG, et al. 2021. Clin Cancer Res. 27:2023. PubMed
  198. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  199. Mesnieres M, et al. 2021. Cell Reports. 36(8):109618. PubMed
  200. Doss PMIA, et al. 2021. Cell Reports. 34(10):108833. PubMed
  201. Caporarello N, et al. 2020. Aging Cell. 19:e13196. PubMed
  202. Huo M, et al. 2017. FASEB J. 10.1096/fj.201601030R. PubMed
  203. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  204. Böhm AM et al. 2019. Dev Cell. 51(2):236-254 . PubMed
  205. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
  206. Chen L, et al. 2021. Theranostics. 11:6668. PubMed
  207. Sugita Y, et al. 2021. Oncol Rep. 45:. PubMed
  208. Yu H, et al. 2021. Cell Death Dis. 13:1. PubMed
  209. Wang R, et al. 2022. J Immunother Cancer. 10:. PubMed
  210. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  211. Gong P, et al. 2022. Cell Death Discov. 8:466. PubMed
  212. Patel K, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.11. PubMed
  213. Tsunekuni K, et al. 2020. J Clin Med. 9:00. PubMed
  214. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  215. Zhang D, et al. 2020. Signal Transduct Target Ther. 5:24. PubMed
  216. Chung S, et al. 2020. Am J Physiol Lung Cell Mol Physiol. L921:318. PubMed
  217. Baron CS, et al. 2018. Nat Commun. 9:2517. PubMed
  218. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  219. Miragaia RJ, et al. 2018. Sci Rep. 8:685. PubMed
  220. Rosen SF, et al. 2022. Genome Med. 14:108. PubMed
  221. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  222. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  223. Liu SS, et al. 2021. Immunity. :. PubMed
  224. Wang Y, et al. 2021. Nat Commun. 0.570833333. PubMed
  225. Gao P, et al. 2020. Front Immunol. 1.636111111. PubMed
  226. Sharma M, et al. 2019. Immunometabolism. 1. PubMed
  227. Liang Z, et al. 2017. Autophagy. 14:505. PubMed
  228. Hsu HP, et al. 2021. J Biol Chem. 296:100419. PubMed
  229. Mansouri S, et al. 2021. J Immunol. 206:2233. PubMed
  230. Chen Y, et al. 2021. Braz J Med Biol Res. 54:e9570. PubMed
  231. Caporarello N, et al. 2022. Nat Commun. 13:4170. PubMed
  232. Deptuch T, et al. 2022. Sci Rep. 12:13480. PubMed
  233. Garcia-Alegria E, et al. 2016. Sci Rep. 6: 25917. PubMed
  234. Kim SI, et al. 2020. Molecular Cancer Therapeutics. 20(1):173-182. PubMed
  235. Durga Devi T, et al. 2017. Am J Pathol. 187:2659. PubMed
  236. Wang L, et al. 2020. Nat Commun. 0.654166667. PubMed
  237. Wirasinha RC, et al. 2021. J Exp Med. 218: . PubMed
  238. Liang Z, et al. 2022. iScience. 25:105233. PubMed
  239. Vogiatzi A, et al. 2021. Mol Cell Biol. 41:e0014921. PubMed
  240. Song X, et al. 2022. Transl Oncol. 15:101306. PubMed
  241. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
  242. Sheriff L, et al. 2020. Dis Model Mech. 13:dmm046383. PubMed
  243. Zheng QY, et al. 2020. FASEB J. 34:10590. PubMed
  244. Omori S, et al. 2020. Cell Metabolism. 32(5):814-828.e6. PubMed
  245. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed
  246. Uematsu T, et al. 2015. Sci Rep. 5: 17577. PubMed
  247. Mitchell LA, et al. 2019. Oncotarget. 10:2252. PubMed
  248. Han Y, et al. 2019. J Clin Invest. 130:26. PubMed
  249. Riopel M, et al. 2019. Mol Metab. 20:89. PubMed
RRID
AB_893344 (BioLegend Cat. No. 103131)
AB_893340 (BioLegend Cat. No. 103132)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD45
Specificity Alt (DOES NOT SHOW ON TDS):
CD45
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD45 on UniProt.org

Related FAQs

How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Other Formats

View All CD45 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD45 30-F11 FC
Biotin anti-mouse CD45 30-F11 FC
FITC anti-mouse CD45 30-F11 FC
PE anti-mouse CD45 30-F11 FC
PE/Cyanine5 anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 30-F11 FC,IHC-F,CyTOF®,IP,CMCD,IHC,WB
PE/Cyanine7 anti-mouse CD45 30-F11 FC
APC/Cyanine7 anti-mouse CD45 30-F11 FC
Alexa Fluor® 488 anti-mouse CD45 30-F11 FC,SB
Alexa Fluor® 647 anti-mouse CD45 30-F11 FC,ICC,IHC,3D IHC,SB
Pacific Blue™ anti-mouse CD45 30-F11 FC
Alexa Fluor® 700 anti-mouse CD45 30-F11 FC,SB
PerCP/Cyanine5.5 anti-mouse CD45 30-F11 FC
PerCP anti-mouse CD45 30-F11 FC
Alexa Fluor® 594 anti-mouse CD45 30-F11 IHC-F,FC,3D IHC
Brilliant Violet 421™ anti-mouse CD45 30-F11 FC,SB
Brilliant Violet 570™ anti-mouse CD45 30-F11 FC
Brilliant Violet 510™ anti-mouse CD45 30-F11 FC
Brilliant Violet 605™ anti-mouse CD45 30-F11 FC
Purified anti-mouse CD45 (Maxpar® Ready) 30-F11 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse CD45 30-F11 FC
Brilliant Violet 711™ anti-mouse CD45 30-F11 FC
Brilliant Violet 785™ anti-mouse CD45 30-F11 FC
Brilliant Violet 650™ anti-mouse CD45 30-F11 FC
APC/Fire™ 750 anti-mouse CD45 30-F11 FC
Brilliant Violet 750™ anti-mouse CD45 30-F11 FC
TotalSeq™-A0096 anti-mouse CD45 30-F11 PG
TotalSeq™-B0096 anti-mouse CD45 30-F11 PG
Ultra-LEAF™ Purified anti-mouse CD45 30-F11 FC,CyTOF®,IP,CMCD,IHC,WB
Spark Blue™ 550 anti-mouse CD45 30-F11 FC
Spark NIR™ 685 anti-mouse CD45 30-F11 FC
TotalSeq™-C0096 anti-mouse CD45 30-F11 PG
Spark YG™ 570 anti-mouse CD45 30-F11 IHC-F
PE/Fire™ 640 anti-mouse CD45 30-F11 FC
APC/Fire™ 810 anti-mouse CD45 30-F11 FC
PE/Fire™ 700 anti-mouse CD45 30-F11 FC
Spark Violet™ 538 anti-mouse CD45 30-F11 FC
Spark YG™ 593 anti-mouse CD45 30-F11 FC
Spark Blue™ 574 anti-mouse CD45 Antibody 30-F11 FC
Spark Blue™ 515 anti-mouse CD45 30-F11 FC
Spark UV™ 387 anti-mouse CD45 30-F11 FC
PE/Fire™ 810 anti-mouse CD45 30-F11 FC
Spark Red™ 718 anti-mouse CD45 (Flexi-Fluor™) 30-F11 FC
Spark PLUS UV™ 395 anti-mouse CD45 30-F11 FC
Go To Top Version: 3    Revision Date: 08.24.2018

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account